← Leaderboards
Clyde S Crumpacker
Beth Israel Deaconess Medical Center
$2,475,664
Attributed
$2,475,664
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,475,664 · 3
By mechanism
R01$1,700,000 · 1
M01$775,664 · 2
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Mary Albrecht$387,832
- David Ives$387,832
- Bruce J Dezube$965,277
- Lorraine Kyne$661,148
- Nezam Hassan Afdhal$3,980,011
Others in their field
Top investigators on “Zidovudine”
- Willard Cates · Family Health International$66,963,584
- Jay B Jackson · Johns Hopkins University$17,529,470
- Stephen J Durako · Westat, Inc.$15,048,684
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$11,770,144
- Marc J Lallemant · Harvard University (Sch Of Public Hlth)$11,626,990
- Laura A Guay · Johns Hopkins University$11,000,941
Research focus
ZidovudineGenetic RegulationHiv InfectionsTissue /Cell CultureHuman SubjectHuman Therapy EvaluationLaboratory MouseLamivudineCombination ChemotherapyVascular Smooth MuscleAids TherapyDisease /Disorder ModelAntiaids AgentClinical ResearchCardiovascular Disorder ChemotherapyCardiovascular InjuryMicroarray TechnologyCardiovascular PharmacologyMicroorganism Disease ChemotherapyNorthern BlottingsCell ProliferationOpen Reading FramesPolymerase Chain ReactionVirus Infection Mechanism
Grant awards (8)
Mechanisms of Vascular Injury By HCMV$425,000
R01 · FY2005 · HL
Mechanisms of Vascular Injury By HCMV$425,000
R01 · FY2004 · HL
Mechanisms of Vascular Injury By HCMV$425,000
R01 · FY2003 · HL
Mechanisms of Vascular Injury By HCMV$425,000
R01 · FY2002 · HL
COMBINATION THERAPY INVOLVING INDINAVIR, ZIDOVUDINE, AND LAMIVUDINE IN HIV$193,916
M01 · FY2000 · RR
ACTG 320--INDINAVIR WITH OPEN LABEL ZIDOVUDINE AND LAMIVUDINE$193,916
M01 · FY2000 · RR
COMBINATION THERAPY INVOLVING INDINAVIR, ZIDOVUDINE, AND LAMIVUDINE IN HIV$193,916
M01 · FY2000 · RR
ACTG 320--INDINAVIR WITH OPEN LABEL ZIDOVUDINE AND LAMIVUDINE$193,916
M01 · FY2000 · RR